International Prostate Symptom Score

The International Prostate Symptom Score (I-PSS) is a seven-item questionnaire that measures the severity of lower urinary tract symptoms in men, most often symptoms linked to benign prostatic hyperplasia. Patients rate seven urinary symptoms over the past month, and a separate eighth question captures how bothered they feel about their current urinary condition.

Why healthcare providers use the I-PSS

Standardized symptom measurement. Converts subjective urinary complaints into a numeric score that supports consistent assessment across visits.
Treatment monitoring. Repeating the questionnaire shows whether symptoms improve, stay stable, or worsen over time.
Shared decision-making. The quality of life question shows how much symptoms bother the patient, which guides clinical decision-making.
Efficient screening. A short self-report form flags men who may need further assessment without a lengthy interview.

Which settings use the I-PSS?

Primary care. Clinicians evaluate urinary complaints and decide when referral or further assessment is warranted.
Urology clinics. Specialists track symptom severity before and after treatment for benign prostatic hyperplasia.
Men's health programs. Staff screen older men who report frequency, urgency, or nighttime urination.

What does the I-PSS measure?

The I-PSS measures the severity of lower urinary tract symptoms over the past month, along with a single quality of life rating. The seven symptom questions cover both storage and voiding complaints and combine into one total symptom score.

Storage symptoms. Daytime frequency, urgency, and nighttime urination (nocturia).
Voiding symptoms. Weak stream, straining, intermittency, and a sense of incomplete emptying.
Quality of life. A separate question on how the patient would feel living with their current urinary symptoms.

Scoring the I-PSS

Number of items. Seven symptom questions, plus one separate quality of life question.
Per-item scale. Each symptom question is scored 0 to 5, from not at all to almost always.
Total score range. 0 to 35 across the seven symptom questions.
Score direction. Higher scores indicate more severe symptoms.

The total score reflects symptom severity, not a diagnosis. The quality of life question is not added to the symptom total and is interpreted alongside it. Scores should be considered with clinical history and examination, and they guide clinical decision-making rather than replace it.

Score	Interpretation	Suggested next step
0 to 7	Mild symptoms	Watchful waiting
8 to 19	Moderate symptoms	Consider further assessment
20 to 35	Severe symptoms	Consider further assessment

Best practices for administration

Use a consistent recall period. Ask patients to rate symptoms over the same past month window each time.
Let patients self-complete. Self-administration saves clinician time; offer help for patients who need it.
Collect a baseline. Record an initial score before any intervention so later scores show change.
Re-administer on a schedule. Repeat at follow-up visits to track response and progression.
Review the quality of life item separately. Discuss the bother score with the patient rather than folding it into the total.

How Zentake helps with the I-PSS

Automatic scoring. Totals on submit, no hand-tallying.
Longitudinal tracking. Re-send on a schedule and view change over time.
Before the visit. Primary care practices have patients complete it from home on any device so the clinician starts informed.
HIPAA compliant. Encrypted, with a signed BAA on every plan.

References

The I-PSS uses the seven symptom questions of the American Urological Association symptom index, developed and validated for benign prostatic hyperplasia by Barry and colleagues (Barry MJ, et al. J Urol. 1992;148(5):1549-1557).

The World Health Organization adopted this index and added a quality of life question to form the I-PSS. The mild (0 to 7), moderate (8 to 19), and severe (20 to 35) severity bands from that work are widely used in urology practice and guidelines.

Last updated: August 2026

International Prostate Symptom Score questions, answered.

What is the I-PSS used for?

The I-PSS is used to measure the severity of lower urinary tract symptoms in men, most often symptoms linked to benign prostatic hyperplasia. Clinicians use the total score to gauge symptom burden, track change over time, and guide clinical decision-making, while a separate question captures how bothered the patient feels.

How many questions are on the I-PSS?

The I-PSS has seven symptom questions covering frequency, urgency, nocturia, weak stream, straining, intermittency, and incomplete emptying. Each is scored from 0 to 5. A separate eighth question rates quality of life on a 0 to 6 scale and is interpreted alongside the total rather than added into it.

What is the total score range for the I-PSS?

The seven symptom questions produce a total score from 0 to 35, where higher scores indicate more severe lower urinary tract symptoms. Published severity bands classify 0 to 7 as mild, 8 to 19 as moderate, and 20 to 35 as severe. The quality of life question is scored and reviewed separately.

How are I-PSS scores interpreted?

The total symptom score is grouped into mild (0 to 7), moderate (8 to 19), and severe (20 to 35) bands. These reflect symptom severity, not a diagnosis. Scores should be considered with clinical history and examination and prompt follow-up or further assessment rather than replacing clinical judgment.

Is the I-PSS the same as the AUA symptom index?

The I-PSS uses the same seven symptom questions as the American Urological Association symptom index published by Barry and colleagues in 1992. The World Health Organization adopted that index and added a single quality of life question, producing the eight-question I-PSS now used internationally.

How often should the I-PSS be repeated?

Record a baseline I-PSS before any intervention, then repeat it at follow-up visits to track whether symptoms improve, stay stable, or worsen. Re-administering the same questionnaire over time makes changes in symptom severity easier to see and supports ongoing clinical decision-making.